By adopting FDA-endorsed primary endpoints that are easier to achieve, Dimerix has bolstered the chances of its phase III kidney drug trial succeeding.
Good morning! Here’s everything you need to know before the ASX flings open its doors and begins trading today.
Barry FitzGerald and Aussie mining legend Norm Seckold dig into Uvre’s newly acquired collection of New Zealand gold projects.
A new report from RFC Ambrian lays out the commanding position China has taken in the gallium market and the outlook for Western players.
Australia’s S&P/ASX 200 rose 1.4% in June 2025 and gained almost 10% for Q2 CY25 brushing aside geopolitical and macroeconomic concerns.
